Kristof De Vusser
Ghent University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kristof De Vusser.
Plant Physiology | 2002
Gerrit T.S. Beemster; Kristof De Vusser; Evelien De Tavernier; Kirsten De Bock; Dirk Inzé
We used a kinematic analysis to investigate the growth processes responsible for variation in primary root growth between 18 ecotypes of Arabidopsis. Root elongation rate differed 4-fold between the slowest (Landsberg erecta, 71 μm h−1) and fastest growing line (Wassilewskija [Ws]; 338 μm h−1). This difference was contributed almost equally by variations in mature cortical cell length (84 μm [Landsbergerecta] to 237 μm [Ws]) and rate of cell production (0.63 cell h−1 [NW108] to 1.83 cell h−1[Ws]). Cell production, in turn, was determined by variation in cell cycle duration (19 h [Tsu] to 48 h [NW108]) and, to a lesser extent, by differences in the number of dividing cells (32 [Weiningen] to 61 [Ws]). We found no correlation between mature cell size and endoreduplication, refuting the hypothesis that the two are linked. However, there was a strong correlation between cell production rates and the activity of the cyclin-dependent kinase (CDKA). The level of the protein could explain 32% of the variation in CDKA. Therefore, it is likely that regulators of CDKA, such as cyclins and inhibitors, are also involved. These data provide a functional link between cell cycle regulation and whole-plant growth rate as affected by genetic differences.
Applied and Environmental Microbiology | 2004
Wouter Vervecken; Vladimir Kaigorodov; Nico Callewaert; Steven Geysens; Kristof De Vusser; Roland Contreras
ABSTRACT The Pichia pastoris N-glycosylation pathway is only partially homologous to the pathway in human cells. In the Golgi apparatus, human cells synthesize complex oligosaccharides, whereas Pichia cells form mannose structures that can contain up to 40 mannose residues. This hypermannosylation of secreted glycoproteins hampers the downstream processing of heterologously expressed glycoproteins and leads to the production of protein-based therapeutic agents that are rapidly cleared from the blood because of the presence of terminal mannose residues. Here, we describe engineering of the P. pastoris N-glycosylation pathway to produce nonhyperglycosylated hybrid glycans. This was accomplished by inactivation of OCH1 and overexpression of an α-1,2-mannosidase retained in the endoplasmic reticulum and N-acetylglucosaminyltransferase I and β-1,4-galactosyltransferase retained in the Golgi apparatus. The engineered strain synthesized a nonsialylated hybrid-type N-linked oligosaccharide structure on its glycoproteins. The procedures which we developed allow glycan engineering of any P. pastoris expression strain and can yield up to 90% homogeneous protein-linked oligosaccharides.
Biotechnology Letters | 2008
Pieter P. Jacobs; Stefan Ryckaert; Steven Geysens; Kristof De Vusser; Nico Callewaert; Roland Contreras
Expression of proteins on the surface of yeasts has a wide range of applications in biotechnology, such as directed evolution of proteins for increased affinity and thermal stability, screening of antibody libraries, epitope mapping, and use as whole-cell biocatalysts. However, hyperglycosylation can interfere with overall protein accessibility on the surface. Therefore, the less elaborate hyperglycosylation in wild type Pichia pastoris and the availability of glycoengineered strains make this yeast an excellent alternative for surface display of glycoproteins. Here, we report the implementation of the well-established a-agglutinin-based yeast surface display technology in P. pastoris. Four heterologous proteins were expressed on the surface of a wild type and a glycoengineered strain. Surface display levels were monitored by Western blot, immunofluorescence microscopy, and FACS analysis. The availability of glycoengineered strains makes P. pastoris an excellent alternative for surface display of glycoproteins and paves the way for new applications.
Glycobiology | 2004
Alicja Woronowicz; Kristof De Vusser; Wouter Laroy; Roland Contreras; Susan O. Meakin; Gregory M. Ross; Myron R. Szewczuk
Glycobiology | 2007
Alicja Woronowicz; Schammim Ray Amith; Kristof De Vusser; Wouter Laroy; Roland Contreras; Sameh Basta; Myron R. Szewczuk
Vaccine | 2008
Germán H. Fontanella; Kristof De Vusser; Wouter Laroy; Lucas Daurelio; Ana L. Nocito; Silvia Revelli; Roland Contreras
Glycobiology | 2007
Alicja Woronowicz; Schammim Ray Amith; Vanessa W Davis; Preethi Jayanth; Kristof De Vusser; Wouter Laroy; Roland Contreras; Susan O. Meakin; Myron R. Szewczuk
Journal of Biotechnology | 2005
Stefan Ryckaert; Vera Martens; Kristof De Vusser; Roland Contreras
Archive | 2007
Roland Contreras; Kristof De Vusser; Silvia Revelli
Journal of Biotechnology | 2005
Stefan Ryckaert; Vera Martens; Kristof De Vusser; Roland Contreras